Narcolepsy

Avadel Pharmaceuticals (NASDAQ:AVDL) slipped by 25.63% in after-hours on Wednesday after it missed the fourth quarter sales estimate by 5.12%. Still, the sales of its narcolepsy drug, LUMRYZ rose by 150% on an annual basis. What Happened: The preliminary earnings results for the fourth quarter...

Takeda Pharmaceutical Company Limited (NYSE: TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral orexin agonist. According to Takeda, TAK 994 was undergoing two Phase 2 trials for narcolepsy Type 1 with cataplexy and...

Needham has initiated Avadel Pharmaceuticals Plc (NASDAQ: AVDL) coverage with a Buy rating and $17 price target.  Analyst Ami Fadia sees an upside of almost 88%. The analyst tells investors that the Company's sodium oxybate launch and sales potential are "...

Health Canada has approved Jazz Pharmaceuticals plc's (NASDAQ: JAZZ) Sunosi (solriamfetol) for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult patients.  Once-daily Sunosi is approved with doses of 75 mg and 150 mg....

The FDA has granted Breakthrough Therapy Designation to Takeda Pharmaceutical Company Limited's (NYSE: TAK) TAK-994 for excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1). The oral orexin agonist is currently in Phase 2 study.  EDS is a...

The FDA has accepted NLS Pharmaceutics Ltd's (NASDAQ: NLSP) Investigational New Drug application for Quilience (mazindol extended-release (mazindol ER), the Company's lead drug candidate, for the treatment of narcolepsy.  The open IND enables NLS to initiate its Phase...

NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead product candidate to treat narcolepsy, Quilience. Narcolepsy is a chronic sleep disorder caused by a deficiency in...

Avadel Pharmaceuticals Plc (NASDAQ: AVDL) has announced the presentation of secondary endpoint data from the Phase 3 REST-ON trial evaluating FT218 once-nightly formulation of sodium oxybate (ON-SXB) for excessive daytime sleepiness and cataplexy in adults with narcolepsy....